{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,19]],"date-time":"2025-11-19T16:53:56Z","timestamp":1763571236554,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T00:00:00Z","timestamp":1598832000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hum Hypertens"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1038\/s41371-020-00406-2","type":"journal-article","created":{"date-parts":[[2020,8,31]],"date-time":"2020-08-31T18:02:36Z","timestamp":1598896956000},"page":"709-717","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Prevalence and clinical profile of refractory hypertension in a large cohort of patients with resistant hypertension"],"prefix":"10.1038","volume":"35","author":[{"given":"Bernardo","family":"Chedier","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2873-1601","authenticated-orcid":false,"given":"Arthur Fernandes","family":"Cortez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4526-7078","authenticated-orcid":false,"given":"Christian Nejm","family":"Roderjan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Aline de Hollanda","family":"Cavalcanti","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fernanda Oliveira de Carvalho","family":"Carlos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bruno Dussoni Moreira","family":"dos Santos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3853-7842","authenticated-orcid":false,"given":"Elizabeth Silaid","family":"Muxfeldt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2020,8,31]]},"reference":[{"key":"406_CR1","doi-asserted-by":"publisher","first-page":"451","DOI":"10.1161\/HYPERTENSIONAHA.113.02026","volume":"63","author":"DA Calhoun","year":"2014","unstructured":"Calhoun DA, Booth JN, Oparil S, Irvin MR, Shimbo D, Lackland DT, et al. Refractory hypertension: determination of prevalence, risk factors, and comorbidities in a large, population-based cohort. Hypertension. 2014;63:451\u20138.","journal-title":"Hypertension."},{"key":"406_CR2","doi-asserted-by":"publisher","first-page":"898","DOI":"10.1161\/HYPERTENSIONAHA.110.168948","volume":"57","author":"A de la Sierra","year":"2011","unstructured":"de la Sierra A, Segura J, Banegas JR, Gorostidi M, de la Cruz JJ, Armario P, et al. Clinical features of 8295 patients with resistant hypertension classified on the basis of ambulatory blood pressure monitoring. Hypertension. 2011;57:898\u2013902.","journal-title":"Hypertension."},{"key":"406_CR3","doi-asserted-by":"publisher","first-page":"1635","DOI":"10.1161\/CIRCULATIONAHA.111.068064","volume":"125","author":"SL Daugherty","year":"2012","unstructured":"Daugherty SL, Powers JD, Magid DJ, Tavel HM, Masoudi FA, Margolis KL, et al. Incidence and prognosis of resistant hypertension in hypertensive patients. Circulation. 2012;125:1635\u201342.","journal-title":"Circulation."},{"key":"406_CR4","doi-asserted-by":"publisher","first-page":"e007365","DOI":"10.1161\/JAHA.117.007365","volume":"6","author":"P Armario","year":"2017","unstructured":"Armario P, Calhoun DA, Oliveras A, Blanch P, Vinyoles E, Banegas JR, et al. Prevalence and clinic characteristics of refractory hypertension. J Am Heart Assoc. 2017;6:e007365.","journal-title":"J Am Heart Assoc."},{"key":"406_CR5","doi-asserted-by":"publisher","first-page":"485","DOI":"10.1007\/s11906-014-0485-1","volume":"16","author":"R Modolo","year":"2014","unstructured":"Modolo R, de Faria AP, Almeida A, Moreno H. Resistant or refractory hypertension: are they different? Curr Hypertens Rep. 2014;16:485.","journal-title":"Curr Hypertens Rep."},{"key":"406_CR6","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1161\/HYPERTENSIONAHA.115.05449","volume":"66","author":"T Dudenbostel","year":"2015","unstructured":"Dudenbostel T, Acelajado MC, Pisoni R, Li P, Oparil S, Calhoun DA. Refractory hypertension: evidence of heightened sympathetic activity as a cause of antihypertensive treatment failure. Hypertension. 2015;66:126\u201333.","journal-title":"Hypertension"},{"key":"406_CR7","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1161\/HYPERTENSIONAHA.118.10965","volume":"72","author":"A Velasco","year":"2018","unstructured":"Velasco A, Siddiqui M, Kreps E, Kolakalapudi P, Dudenbostel T, Arora G, et al. Refractory hypertension is not attributable to intravascular fluid retention as determined by intracardiac volumes. Hypertension. 2018;72:343\u20139.","journal-title":"Hypertension"},{"key":"406_CR8","doi-asserted-by":"crossref","unstructured":"Carey RM, Calhoun DA, Bakris GL, Brook RD, Daugherty Sl, Dennison-Himmelfarb CR, et al. American heart association professional\/public education and publications committee of the council on hypertension; councilon cardiovascular and stroke nursing; council on clinical cardiology; council on genomic and precision medicine; council on peripheral vascular disease; council on quality of care and outcomes research; and stroke council. Resistant hypertension: detection, evaluation, and management. A scientific statement from the American heart association. Hypertension. 2018;72:e53\u201390.","DOI":"10.1161\/HYP.0000000000000084"},{"key":"406_CR9","doi-asserted-by":"publisher","first-page":"1953","DOI":"10.1097\/HJH.0000000000001940","volume":"36","author":"B Williams","year":"2018","unstructured":"Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al. 2018 ESC\/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension: the task force for the management of arterial hypertension of the European society of cardiology and the European society of hypertension. J Hypertens. 2018;36:1953\u20132041.","journal-title":"J Hypertens."},{"key":"406_CR10","doi-asserted-by":"publisher","first-page":"2979","DOI":"10.1590\/S0102-311X2008001200030","volume":"24","author":"KV Bloch","year":"2008","unstructured":"Bloch KV, Melo AN, de, Nogueira AR. Prevalence of anti-hypertensive treatment adherence in patients with resistant hypertension and validation of three indirect methods for assessing treatment adherence. Cad Saude Publica. 2008;24:2979\u201384.","journal-title":"Cad Saude Publica."},{"key":"406_CR11","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1007\/s11906-005-0008-1","volume":"7","author":"MN Pratt-Ubunama","year":"2005","unstructured":"Pratt-Ubunama MN, Nishizaka MK, Calhoun DA. Aldosterone antagonism: an emerging strategy for effective blood pressure lowering. Curr Hypertens Rep. 2005;7:186\u201392.","journal-title":"Curr Hypertens Rep."},{"key":"406_CR12","doi-asserted-by":"publisher","first-page":"1269","DOI":"10.1161\/HYP.0000000000000066","volume":"71","author":"PK Whelton","year":"2018","unstructured":"Whelton PK, Carey RM, Aronow WS, Casey DE Jr, Collins KJ, Dennison Himmelfarb C, et al. 2017 ACC\/AHA\/AAPA\/ABC\/ACPM\/AGS\/APhA\/ASH\/ ASPC\/NMA\/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American college of cardiology\/American heart association task force on clinical practice guidelines. Hypertension. 2018;71:1269\u2013324.","journal-title":"Hypertension."},{"key":"406_CR13","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1097\/00126097-200208000-00006","volume":"7","author":"MA El Assaad","year":"2002","unstructured":"El Assaad MA, Topouchian JA, Darn\u00e9 BM, Asmar RG. Validation of the Omron HEM-907 device for blood pressure measurement. Blood Press Monit. 2002;7:237\u201341.","journal-title":"Blood Press Monit."},{"key":"406_CR14","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1097\/00126097-200008000-00007","volume":"5","author":"CR Jones","year":"2000","unstructured":"Jones CR, Taylor K, Chowienczyk P, Poston L, Shennan AH. A validation of the Mobil OGraph (version 12) ambulatory blood pressure monitor. Blood Press Monit. 2000;5:233\u20138.","journal-title":"Blood Press Monit"},{"key":"406_CR15","doi-asserted-by":"publisher","first-page":"1359","DOI":"10.1097\/HJH.0000000000000221","volume":"32","author":"G Parati","year":"2014","unstructured":"Parati G, Stergiou G, O\u2019Brien E, Asmar R, Beillin L, Bilo G, et al. European society of hypertension practice guidelines for ambulatory blood pressure monitoring. J Hypertens. 2014;32:1359\u201366.","journal-title":"J Hypertens"},{"key":"406_CR16","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1097\/HJH.0b013e32834fa8b0","volume":"30","author":"LM Van Bortel","year":"2012","unstructured":"Van Bortel LM, Laurent S, Boutouyrie P, Chowienczyk P, Cruickshank JK, De Backer T, et al. Artery society; European society of hypertension working group on vascular structure and function; European network for noninvasive investigation of large arteries. Expert consensus document on the measurement of aortic stiffness in daily practice using carotid-femoral pulse wave velocity. J Hypertens. 2012;30:445\u20138.","journal-title":"J Hypertens."},{"key":"406_CR17","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1111\/j.1751-7176.2011.00556.x","volume":"14","author":"MC Acelajado","year":"2012","unstructured":"Acelajado MC, Pisoni R, Dudenbostel T, Dell\u2019Italia LJ, Cartmill F, Zhang B, et al. Refractory hypertension: definition, prevalence, and patient characteristics. J Clin Hypertens. 2012;14:7\u201312.","journal-title":"J Clin Hypertens."},{"key":"406_CR18","doi-asserted-by":"publisher","first-page":"1797","DOI":"10.1097\/HJH.0000000000002103","volume":"37","author":"MG Buhnerkempe","year":"2019","unstructured":"Buhnerkempe MG, Botchway A, Prakash V, Al-Akchar M, Nolasco Morales CE, Calhoun DA, et al. Prevalence of refractory hypertension in the United States from 1999 to 2014. J Hypertens 2019;37:1797\u2013804.","journal-title":"J Hypertens"},{"key":"406_CR19","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1161\/HYPERTENSIONAHA.109.140988","volume":"55","author":"F de Souza","year":"2010","unstructured":"de Souza F, Muxfeldt E, Fiszman R, Salles G. Efficacy of spironolactone therapy in patients with true resistant hypertension. Hypertension. 2010;55:147\u201352.","journal-title":"Hypertension"},{"key":"406_CR20","first-page":"pii: e430","volume":"3","author":"T Dudenbostel","year":"2017","unstructured":"Dudenbostel T, Siddiqui M, Gharpure N, Calhoun DA. Refractory versus resistant hypertension: novel distinctive phenotypes. J Nat Sci 2017;3:pii: e430.","journal-title":"J Nat Sci"},{"key":"406_CR21","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1016\/j.jash.2015.03.005","volume":"9","author":"R Modolo","year":"2015","unstructured":"Modolo R, de Faria AP, Sabbatini AA, Barbaro NR, Ritter AM, Moreno H. Refractory and resistant hypertension: characteristics and differences observed in a specialized clinic. J Am Soc Hypertens. 2015;9:397\u2013402.","journal-title":"J Am Soc Hypertens."},{"key":"406_CR22","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/j.cjca.2012.03.010","volume":"28","author":"D Clark 3rd","year":"2012","unstructured":"Clark D 3rd, Ahmed MI, Calhoun DA. Resistant hypertension and aldosterone: an update. Can J Cardiol. 2012;28:318\u201325.","journal-title":"Can J Cardiol."},{"key":"406_CR23","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.amjmed.2016.01.039","volume":"129","author":"M Epstein","year":"2016","unstructured":"Epstein M, Duprez DA. Resistant hypertension and the pivotal role for mineralocorticoid receptor antagonists: a clinical update 2016. Am J Med. 2016;129:661\u20136.","journal-title":"Am J Med."},{"key":"406_CR24","doi-asserted-by":"publisher","first-page":"2","DOI":"10.1007\/s11906-017-0704-7","volume":"19","author":"JE Sharman","year":"2017","unstructured":"Sharman JE, Boutouyrie P, Laurent S. Arterial (Aortic) stiffness in patients with resistant hypertension: from assessment to treatment. Curr Hypertens Rep. 2017;19:2.","journal-title":"Curr Hypertens Rep."},{"key":"406_CR25","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1007\/s10741-018-9758-0","volume":"24","author":"CJ Kapelios","year":"2019","unstructured":"Kapelios CJ, Murrow JR, N\u00fchrenberg TG, Montoro Lopez MN. Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials. Heart Fail Rev. 2019;24:367\u201377.","journal-title":"Heart Fail Rev."},{"key":"406_CR26","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1038\/jhh.2014.83","volume":"29","author":"A Gupta","year":"2015","unstructured":"Gupta A, Schiros CG, Gaddam KK, Aban I, Denney TS, Lloyd SG, et al. Effect of spironolactone on diastolic function in hypertensive left ventricular hypertrophy. J Hum Hypertens. 2015;29:241\u20136.","journal-title":"J Hum Hypertens."},{"key":"406_CR27","doi-asserted-by":"publisher","first-page":"1453","DOI":"10.1159\/000430310","volume":"36","author":"MD Cezar","year":"2015","unstructured":"Cezar MD, Damatto RL, Pagan LU, Lima AR, Martinez PF, Bonomo C, et al. Early spironolactone treatment attenuates heart failure development by improving myocardial function and reducing fibrosis in spontaneously hypertensive rats. Cell Physiol Biochem. 2015;36:1453\u201366.","journal-title":"Cell Physiol Biochem."},{"key":"406_CR28","first-page":"809","volume":"6","author":"J Ma","year":"2014","unstructured":"Ma J, Zhang H, Guo H, Xu Y. Effects of low-dose spironolactone combined with irbesartan on cardiac hypertrophy induced by pressure overload in rats. Am J Transl Res. 2014;6:809\u201319.","journal-title":"Am J Transl Res."},{"key":"406_CR29","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/hr.2013.17","volume":"36","author":"ES Muxfeldt","year":"2013","unstructured":"Muxfeldt ES, Salles GF. How to use ambulatory blood pressure monitoring in resistant hypertension. Hypertens Res. 2013;36:385\u20139.","journal-title":"Hypertens Res."},{"key":"406_CR30","doi-asserted-by":"publisher","first-page":"645","DOI":"10.1161\/HYPERTENSIONAHA.117.09464","volume":"70","author":"M Siddiqui","year":"2017","unstructured":"Siddiqui M, Judd EK, Oparil S, Calhoun DA. White-coat effect is uncommon in patients with refractory hypertension. Hypertension. 2017;70:645\u201351.","journal-title":"Hypertension."},{"key":"406_CR31","doi-asserted-by":"publisher","first-page":"874","DOI":"10.1001\/archinternmed.2009.68","volume":"169","author":"ES Muxfeldt","year":"2009","unstructured":"Muxfeldt ES, Cardoso CRL, Salles GF. Prognostic value of nocturnal blood pressure reduction in resistant hypertension. Arch Intern Med. 2009;169:874\u201380.","journal-title":"Arch Intern Med."},{"key":"406_CR32","doi-asserted-by":"publisher","first-page":"766","DOI":"10.1038\/s41371-019-0255-2","volume":"33","author":"S Dineva","year":"2019","unstructured":"Dineva S, Uzunova K, Pavlova V, Filipova E, Kalinov K, Vekov T. Comparative efficacy and safety of chlorthalidone and hydrochlorothiazide\u2014meta-analysis. J Hum Hypertens. 2019;33:766\u201374.","journal-title":"J Hum Hypertens"}],"container-title":["Journal of Human Hypertension"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41371-020-00406-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-020-00406-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41371-020-00406-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,30]],"date-time":"2021-08-30T23:05:29Z","timestamp":1630364729000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41371-020-00406-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,31]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["406"],"URL":"https:\/\/doi.org\/10.1038\/s41371-020-00406-2","relation":{},"ISSN":["0950-9240","1476-5527"],"issn-type":[{"type":"print","value":"0950-9240"},{"type":"electronic","value":"1476-5527"}],"subject":[],"published":{"date-parts":[[2020,8,31]]},"assertion":[{"value":"26 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 July 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 August 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 August 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}